title: AIDS is your business.
abstract: If your company operates in a developing country, AIDS is your business. While Africa has received the most attention, AIDS is also spreading swiftly in other parts of the world. Russia and Ukraine had the fastest-growing epidemics last year, and many experts believe China and India will suffer the next tidal wave of infection. Why should executives be concerned about AIDS? Because it is destroying the twin rationales of globalization strategy-cheap labor and fast-growing markets--in countries where people are heavily affected by the epidemic. Fortunately, investments in programs that prevent infection and provide treatment for employees who have HIV/AIDS are profitable for many businesses--that is, they lead to savings that outweigh the programs' costs. Due to the long latency period between HIV infection and the onset of AIDS symptoms, a company is not likely to see any of the costs of HIV/AIDS until five to ten years after an employee is infected. But executives can calculate the present value of epidemic-related costs by using the discount rate to weigh each cost according to its expected timing. That allows companies to think about expenses on HIV/AIDS prevention and treatment programs as investments rather than merely as costs. The authors found that the annual cost of AIDS to six corporations in South Africa and Botswana ranged from 0.4% to 5.9% of the wage bill. All six companies would have earned positive returns on their investments if they had provided employees with free treatment for HIV/AIDS in the form of highly active antiretroviral therapy (HAART), according to the mathematical model the authors used. The annual reduction in the AIDS "tax" would have been as much as 40.4%. The authors' conclusion? Fighting AIDS not only helps those infected; it also makes good business sense.
authors.affiliation: Boston University School of Public Health's Center for International Health, USA.
authors.forename: Sydney
authors.initials: S
authors.lastname: Rosen
authors.forename: Jonathon
authors.initials: J
authors.lastname: Simon
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Vincent
authors.forename: William
authors.initials: W
authors.lastname: MacLeod
authors.forename: Matthew
authors.initials: M
authors.lastname: Fox
authors.forename: Donald M
authors.initials: DM
authors.lastname: Thea
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics; D001902:Botswana / Q000453:epidemiology; D003132:Commerce / Q000191:economics*; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D003906:Developing Countries / Q000191:economics; D017049:Employer Health Costs; D004651:Employment; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D006801:Humans; D038622:Internationality; D007449:Investments / Q000191:economics*; D008875:Middle Aged; D009786:Occupational Health Services / Q000191:economics*; D013019:South Africa / Q000453:epidemiology